The Readout Loud
257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Eli Lilly’s investigational medicine for Alzheimer’s met its goals in an all-important clinical trial, and we explain the results, their implications, and the backstory of what could be a blockbuster drug. We also discuss the latest news in the life sciences, including a busy week of earnings, a long-awaited FDA approval, and the highlights from STAT’s Breakthrough Summit in San Francisco.